
Reproductive Health Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Description
Reproductive Health Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Reproductive Health Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Reproductive Health Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Reproductive Health Devices includes Endometrial Ablation Devices, Female Sterilization Devices, Reversible Contraceptive Devices and Assisted Reproductive Technology Devices.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Reproductive Health Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Reproductive Health Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Reproductive Health Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
153 Pages
- About GlobalData
- Reproductive Health Devices Overview
- Reproductive Health Devices - Pipeline Products by Stage of Development
- Reproductive Health Devices - Pipeline Products by Segment
- Reproductive Health Devices - Pipeline Products by Territory
- Reproductive Health Devices - Pipeline Products by Regulatory Path
- Reproductive Health Devices - Pipeline Products by Estimated Approval Date
- Reproductive Health Devices - Ongoing Clinical Trials
- Reproductive Health Devices Companies - Pipeline Products by Stage of Development
- Reproductive Health Devices – Companies Pipeline Products by Stage of Development
- 3Daughters Inc Company Overview
- Ablatus Therapeutics Ltd Company Overview
- AdneXXA LLC Company Overview
- Agile Therapeutics Inc Company Overview
- AltaScience Limited Company Overview
- Alydia Health Inc Company Overview
- Autoivf Inc Company Overview
- Bayer AG Company Overview
- Bioceptive Inc Company Overview
- Biorings LLC Company Overview
- BioTex Inc Company Overview
- Ceragenix Pharmaceuticals, Inc. (Inactive) Company Overview
- Contrel Europe NV Company Overview
- Dare Bioscience Inc Company Overview
- Dartmouth College Company Overview
- Emblation Ltd Company Overview
- EVE Medical Systems Ltd Company Overview
- Evestra Inc Company Overview
- Evofem Biosciences Inc Company Overview
- Femasys Inc Company Overview
- FemSuite LLC Company Overview
- Ghent University Company Overview
- Healthcare Enterprise Group PLC (Inactive) Company Overview
- Hemosquid SAS Company Overview
- Hera Health Solutions Company Overview
- HLL Lifecare Ltd Company Overview
- Idoman Teoranta Company Overview
- Impres Medical, Inc. Company Overview
- INVO Bioscience Inc Company Overview
- Japanese Organization for Medical Device Development Inc Company Overview
- Johns Hopkins University Company Overview
- Keratin Biosciences Inc Company Overview
- Laboratoire HRA Pharma SAS Company Overview
- Lubrizol Life Science Health Company Overview
- May Health Company Overview
- Memorial Sloan Kettering Cancer Center Company Overview
- Memphasys Ltd Company Overview
- Menorrx LLC Company Overview
- Merck & Co Inc Company Overview
- Merck Serono SA Company Overview
- NextGem Inc Company Overview
- Nipro Corp Company Overview
- Novomedics L L C Company Overview
- OCON Medical Ltd Company Overview
- OncoGenesis Company Overview
- Otago Innovation Ltd Company Overview
- Pfizer Inc Company Overview
- Sebela Pharmaceuticals Inc Company Overview
- Shandong Junxiu Biotechnology Co Ltd Company Overview
- Teva Pharmaceuticals USA Inc Company Overview
- Teva Women's Health Company Overview
- University of California San Diego Company Overview
- University of Cape Town Company Overview
- University of Minnesota Company Overview
- University of Oxford Company Overview
- University of Texas at Austin Company Overview
- University of Texas Health Science Center at San Antonio Company Overview
- University of Washington Company Overview
- Womed Company Overview
- Yale University Company Overview
- ZR-Operculum, Inc. Company Overview
- Feb 06, 2024: Alife Health Partners with Ovation Fertility on Cutting-Edge AI Technology for Embryo Image Capture and Cataloguing
- Jan 26, 2024: Femasys Begins Fembloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
- Jan 23, 2024: Femasys Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- Jan 16, 2024: Pherdal, the First and Only Sterile At-Home Insemination Kit, Awarded FDA Clearance; Now Accepting Pre-orders
- Jan 04, 2024: Hannah Life Technologies Receives 510(K) Clearance For Twoplus Applicator
- Jan 04, 2024: Daree Bioscience's Dare-LARC1 Platform Technology Achieves Proof-of-Concept Device That Has Transformative Potential for Women's Health as Well as in Treating a Broad Range of Diseases
- Jan 02, 2024: Distribution Agreement with Vitrolife Expands – Agreements now in place for Canada & NZ
- Dec 26, 2023: PherDal Fertility Science Receives 510(k) Clearance for PherDal At-Home Insemination Kit
- Dec 18, 2023: Femasys starts birth control solution trial at Stanford Medicine
- Dec 16, 2023: Mosie Receives FDA 510(k) Clearance for Mosie Baby Kit
- Dec 06, 2023: Mosie Baby Becomes the First Company to Receive FDA Clearance for At-Home Intravaginal Insemination
- Dec 06, 2023: Artificial Insemination Kit Granted FDA Clearance
- Dec 04, 2023: Dare Bioscience Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Nov 29, 2023: Start-up Competition Winners Develop Innovative Tumor Antibody Penetration Technology
- Nov 06, 2023: Celanese Announces New Leadership Appointments to Enhance Value Creation
- Nov 06, 2023: NN Reports Financial Results for Third Quarter 2023
- Nov 06, 2023: Celanese Corporations Q3 2023 Earnings Report Strong Profitability and Revenue Growth with Room for Improvement
- Oct 30, 2023: Sebela Women's Health Announces Further Positive Data From the Pivotal Phase 3 Study of the Investigational Copper 175 mm² Intra-Uterine Device (IUD)
- Oct 25, 2023: Femasys to Showcase FemBloc and its other Novel Products Advancing Women's Health at the American Association of Gynecologic Laparoscopic Surgeons
- Sep 27, 2023: Femasys Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
- Sep 21, 2023: Dare Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology Dare-LARC1
- Sep 20, 2023: Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
- Sep 14, 2023: First Real-World Observational Study of the JADA System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG's Obstetrics & Gynecology
- Aug 22, 2023: NN Announces David Harrison as Chief Procurement Officer
- Aug 18, 2023: DonneVie Medical Technology Receives 510(k) Clearance for Dewin Blastocyst Medium
- Aug 03, 2023: Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- Jul 27, 2023: Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
- Jul 26, 2023: A Study Postulates Vaginal Self-Sample and Urine as Applicable Tools for Endometrial Cancer Diagnosis and Prognosis
- Jul 13, 2023: Memphasys Granted Two New Australian Patents for the Felix System
- Jun 27, 2023: NN Promotes Verlin Bush to Chief Commercial Officer
- Jun 26, 2023: Femasys Announces FDA Approval of Its IDE for the Pivotal Clinical Trial of Fembloc Permanent Birth Control, a Non-surgical Alternative for Women
- Jun 26, 2023: May Health Announces Data From Feasibility Studies of its Novel Ovarian Rebalancing Treatment and Receives Approval From FDA for Pivotal Trial
- Jun 21, 2023: Revolutionising Reproductive And Sexual Health: LifeCell Launches Advanced Self- Collection Healthcare Services
- Jun 06, 2023: Study Shows Felix System Offers Significant Advantages Over Alternative Sperm Separation Techniques on Cryopreserved Semen
- May 25, 2023: Zhejiang Horizon Medical Technology receives 510(k) clearance for CryoX Vitrification Freeze Kit / Thaw Kit
- May 18, 2023: Sebela Women's Health announces positive phase 3 data for its investigational, nextgeneration, hormone-free, low-dose copper intrauterine device (IUD)
- May 11, 2023: Femasys to showcase four products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
- Mar 16, 2023: Aspivix announces the publication, in contraception, an international reproductive health journal, of the first-in-women study results using its novel cervical stabilizer in IUD procedures
- Mar 09, 2023: NN Reports Financial Results For Fourth Quarter and Full Year 2022
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.